The Trump administration’s healthcare priorities have mainly focused on replacing the Affordable Care Act or reforming Medicaid, leading to concerns that value-based purchasing efforts will be left in the dust, said David M. Cutler, PhD, of Harvard University.
The Trump administration’s healthcare priorities have mainly focused on replacing the Affordable Care Act (ACA) or reforming Medicaid, leading to concerns that value-based purchasing efforts will be left in the dust, said David M. Cutler, PhD, of Harvard University.
Transcript (slightly modified)
Do you think this country’s trajectory of moving to value-based care will be altered under the current administration?
The move towards value-based care is, of course, an extremely important one. I have not heard the Trump administration say what its philosophy is about this. I am worried on 2 counts. One is, many of the programs that the Obama administration had started are either being slowed down or being cancelled entirely, which I don’t think is good news. But second, I also think their attention is elsewhere, so their attention is on repealing the ACA, or what should be in a replacement bill, or on Medicaid and work requirements.
Their attention isn’t on value-based purchasing. That suggests to me that they’re not going to be actively thinking about it, and this is one of those topics that you kind of have to put the effort into doing, because it doesn’t happen on its own.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More